Ramos MKG, Fuentes MMV

Language: Spanish
References: 23
Page:
PDF size: 195.29 Kb.

ABSTRACT

This publication article presents research on the impact of vaccination on the reduction of mortality and positivity of COVID-19 cases in Honduras. Data were collected from hospitals and healthcare centers in the Metropolitan Region of San Pedro Sula and the Copán Departmental Health Region. A total of 123,148 samples were analyzed, of which 47,578 were positive, with a positivity rate of 38.63%. There were 1,827 deaths recorded in both locations. Additionally, a reduction in the number of deaths was observed in the months of October and November due to participation in the vaccination process. The importance of unvaccinated individuals getting vaccinated is emphasized.

REFERENCES

1. La Secretaría de Salud confirma los dos primeros casos de COVID-19 en el territorio hondureño. UNICEF [Internet]. 11 de marzo, 2020 [citado el 11 de enero, 2022]. Disponible en: https://www.unicef.org/honduras/comunicados-prensa/la-secretar%C3%ADa-de-salud-confirma-los-dos-primeros-casos-de-covid-19-en-el

2. Alvarado-Socarras JL, Vesga-Varela AL, Quintero-Lesmes DC, Fama-Pereira MM, Serrano-Diaz NC, Vasco M, Carballo-Zarate V, Zambrano LI, Paniz-Mondolfi A, Rodriguez-Morales AJ. Perception of COVID-19 Vaccination Amongst Physicians in Colombia. Vaccines (Basel). Mar 19, 2021;9(3):287. DOI: 10.3390/vaccines9030287. PMID: 33808918; PMCID: PMC8003713.

3. Canales Beltrán MT, Valdez PR, Pugliese F, Castagna R, Huespe IA, Boietti B, Pollan JA, Funke N, Leiding B, Gómez-Varela D. Development and evaluation of a machine learning-based in-hospital COVID-19 disease outcome predictor (CODOP): A multicontinental retrospective study. Elife. May 17, 2022;11:e75985. DOI: 10.7554/eLife.75985. PMID: 35579324; PMCID: PMC9129872.

4. Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study. EClinicalMedicine. Jul 22, 2023;62:102109. DOI: 10.1016/j.eclinm.2023.102109. PMID: 37533419; PMCID: PMC10391925.

5. Pérez Abreu MR, Gómez Tejeda JJ, Dieguez Guach RA. Características clínico-epidemiológicas de la COVID-19. Rev haban cienc méd [Internet]. 2020 [citado el 12 de enero, 2022]; 19(2):e_3254. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3254/2505

6. Ramírez C, Herrera Paz EF, Gómez Ventura S, Rodríguez G, Linarez N, Durón RM. Dealing with perceptions related to thrombosis and COVID-19 vaccines. Rev Panam Salud Publica. Jul 08, 2021;45:e45. DOI: 10.26633/RPSP.2021.45. PMID: 34249121; PMCID: PMC8260884.

7. Ávila-Agüero ML, Ospina-Henao S, Pirez MC, Gentile Á, Araya S, Brea J, Mendoza L, Falleiros-Arlant LH. Latin American forum on immunization services during the COVID-19 pandemic. Expert Rev Vaccines. Mar, 2021;20(3):231-234. DOI: 10.1080/14760584.2021.1886930. Epub 2021 Feb 20. PMID: 33554682.

8. Savarino S, Sridhar S; VAT00008 study team. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study. EClinicalMedicine. Sep 12, 2023;64:102168. DOI: 10.1016/j.eclinm.2023.102168. PMID: 37936652; PMCID: PMC10626161.

9. Reyes EB, Saldarriaga C, Schwartzmann P, Sim Kheng Leng D, Trivi M, Yotov YT, Zieroth S. OPTIMIZE Heart Failure Care program coordinators. The impact of the COVID-19 pandemic on heart failure management: Global experience of the OPTIMIZE Heart Failure Care network. Int J Cardiol. Sep 15, 2022;363:240-246. DOI: 10.1016/j.ijcard.2022.06.022. Epub 2022 Jun22. PMID: 35750302; PMCID: PMC9217066.

10. Rodriguez-Morales AJ, Lopez-Echeverri MC, Perez-Raga MF, Quintero-Romero V, Gonzales-Zamora JA, Ulloa-Gutiérrez R. The global challenges of the long COVID-19 in adults and children. Travel Med Infect Dis. Jul-Aug, 2023;54:102606. DOI: 10.1016/j.tmaid.2023.102606. Epub 2023 Jun 8. PMID: 37295581; PMCID: PMC10247301.

11. Honduras recibe las primeras vacunas COVID-19 a través del Mecanismo COVAX. Organización Panamericana de la Salud [Internet]. 16 de marzo, 2021 [citado el 12 de enero, 2022]. Disponible en: https://www.unicef.org/honduras/comunicados-prensa/la-secretar%C3%ADa-de-salud-confirma-los-dos-primeros-casos-de-covid-19-en-el

12. Honduras ha aplicado más de siete millones de vacunas contra el Covid-19. [Internet]. 18 de noviembre, 2021 [citado el 12 de enero, 2022]. Disponible en: https://www.salud.gob.hn/site/index.php/component/k2/item/2447-honduras-ha-aplicado-mas-de-siete-millones-de-vacunas-contra-el-covid-19

13. Muestras, positividad, mortalidad de hospitales, centros de salud y por semanas. La Gran Central Metropolitana San Pedro Sula [Investigación]. 1º de enero a noviembre de 2021.

14. Diazgranados CA, Savarino S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect Dis. May, 2022;22(5):636-648. DOI: 10.1016/S1473-3099(21)00764-7. Epub 2022 Jan 25. PMID: 35090638; PMCID: PMC8789245.

15. Muestras, positividad, mortalidad de municipios y por meses. La Región de Salud Departamental de Copán [Investigación]. Marzo de 2020 a noviembre de 2021.

16. Pedraza L, Villela R, Kamatgi V, Cocuzzo K, Correa R, Lisigurski MZ. The Impact of COVID-19 in the Latinx Community. HCAHealthc J Med. Jun 28, 2022;3(3):97-104. DOI: 10.36518/2689-0216.1387. PMID: 37424622; PMCID: PMC10324846.

17. Caycho-Rodríguez T, Tomás JM, Yupanqui-Lorenzo DE, Valencia PD, Carbajal-León C, Vilca LW, Ventura-León J, Vergara I, Vega D, Shulmeyer MK, Barria-Asenjo NA, Urrutia Rios HT, Lira Lira AE. Relationship Between Fear of COVID-19, Conspiracy Beliefs About Vaccines and Intention to Vaccinate Against COVID-19: A Cross-National Indirect Effect Model in 13 Latin American Countries. Eval Health Prof. Dec, 2023;46(4):371-383. DOI: 10.1177/01632787231186621. Epub 2023 Jul 13. PMID: 37439361; PMCID: PMC10345832.

18. Jiménez Quinteros M, Enriquez Navas M, Arroba R. Innovation and immunization program management: traceability and quality in Latin America and the Caribbean, laying the groundwork for a regional action plan. Expert Rev Vaccines. Aug, 2022;21(8):1023-1028. DOI: 10.1080/14760584.2022.2077195. Epub 2022 May 18. PMID: 35549597.

19. Llau AF, Williams ML, Tejada CE. National vaccine coverage trends and funding in Latin America and the Caribbean. Vaccine. Jan 08, 2021;39(2):317-323. DOI: 10.1016/j.vaccine.2020.11.059. Epub 2020 Dec 4. PMID: 33288342.

20. Tapia-Conyer R, Betancourt-Cravioto M, Saucedo-Martínez R, Motta-Murguía L, Gallardo-Rincón H. Strengthening vaccination policies in Latin America: an evidence-based approach. Vaccine. Aug 20, 2013;31(37):3826-33. DOI: 10.1016/j.vaccine.2012.12.062. Epub 2013 Jan 25. PMID: 23357196.

21. Ronksley P, Scory T, Weaver R, Lunney M, Rodin R, Tonelli M. The impact of vaccination status on importation of COVID-19 among international travellers. Can Commun Dis Rep. Nov 10, 2021;47(11):473-475. DOI: 10.14745/ccdr.v47i11a05. PMID: 34880709; PMCID: PMC8601101.

22. Tampi M, Carrasco-Labra A, O'Brien KK, Velandia-González M, Brignardello-Petersen R. Systematic review on reducing missed opportunities for vaccinations in LatinAmerica.Rev Panam Salud Publica. Jun 21, 2022;46:e65. DOI: 10.26633/RPSP.2022.65. PMID: 35747470; PMCID: PMC9211032.

23. WHO Solidarity Trial Consortium; Pan H, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. Feb 11, 2021;384(6):497-511. DOI: 10.1056/NEJMoa2023184. Epub 2020 Dec 2. PMID: 33264556; PMCID: PMC7727327.